Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipilimumab, Nivolumab and Cryoablation in Early Stage Breast Cancer
NCT02833233Phase 1Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jun 2016
- Primary completion
- Jun 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ipilimumab and nivolumab in breast cancer, sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Number of Participants Evaluated for Adverse Events at 12 weeks. Started Jun 2016; status: completed.
02
Drugs
ipilimumabnivolumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02833233.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02833233.